Lamictal

Lamotrigine, the active ingredient in Lamictal, is an anticonvulsant presented as a tablet for oral use. It is employed to control partial seizures, prevent generalized tonic‑clonic seizures, and provide long‑term mood stabilization as maintenance therapy for bipolar disorder in adult patients. It is approved in the European Union and widely used in clinical practice for seizure control and mood stabilization.

GNH USA supplies Lamictal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured product availability across regulated markets with robust logistics and compliance support for cross‑border procurement.

Lamotrigine is used in the management of several neurologic and psychiatric conditions.

- Partial seizures: reduces the frequency and severity of focal onset seizures. - Generalized tonic‑clonic seizures: helps prevent convulsive seizures in patients with epilepsy. - Bipolar disorder (maintenance therapy): stabilizes mood and decreases recurrence of depressive and manic episodes.

Lamotrigine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate pain often transient. - Dizziness: sensation of light‑headedness, especially at treatment initiation. - Nausea: gastrointestinal upset that may improve over time. - Rash: mild skin irritation or erythema. - Insomnia: difficulty falling or staying asleep. - Blurred vision: temporary visual disturbances.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Toxic epidermal necrolysis: life‑threatening skin detachment. - Blood dyscrasias: aplastic anemia, agranulocytosis, or leukopenia. - Hepatic failure: signs of liver injury such as jaundice. - Severe hypersensitivity reactions: including fever, lymphadenopathy, and organ involvement. - Multiorgan involvement: rare systemic immune‑mediated events.

When prescribing lamotrigine, several safety considerations are essential.

- Pregnancy: Category C; discuss potential risks and benefits with the prescriber. - Renal impairment: dose adjustment may be required; monitor renal function. - Hepatic impairment: consider lower starting dose and monitor liver enzymes. - Concomitant valproate therapy: increased risk of severe skin reactions; initiate lamotrigine at a reduced dose. - Abrupt discontinuation: may precipitate seizure recurrence; taper gradually under medical supervision. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Lamotrigine interacts with several medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Valproic acid: markedly increases lamotrigine serum levels and risk of skin reactions. - Carbamazepine: induces metabolism, reducing lamotrigine concentrations. - Phenytoin: accelerates lamotrigine clearance, lowering efficacy. - Oral contraceptives: decrease lamotrigine levels, potentially reducing seizure control. - Strong enzyme inducers (e.g., rifampin, phenobarbital): lower lamotrigine exposure.

Moderate Interactions (Monitor Closely): - Other antiepileptics (e.g., phenobarbital, primidone): may alter lamotrigine levels; monitor therapeutic response. - Serotonergic agents (e.g., SSRIs, tramadol): rare reports of serotonin syndrome; observe for symptoms. - Immunosuppressants (e.g., azathioprine): potential additive bone‑marrow suppression; check blood counts.